Denmark· DK-28105582114
Sivextro
A tedizolid product containing tedizolidphosphat, registered in Denmark by Merck Sharp & Dohme B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Tedizolid is registered in 14 of 19 countries.
Countries holding a registration under ATC J01XX11 (tedizolid), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Tedizolid · ATC J01XX11
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tedizolid costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tedizolid · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- IT Italy$346.95
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Tedizolidphosphat
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Denmark (DK)
- ATC code
- J01XX11
- ATC class
- Tedizolid
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105582114
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
51 interactions on record for tedizolid.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tedizolid · interactions on record
51 records
- 2 severe
- 49 moderate
Most severe, free to view
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- Sodium picosulfateA06AB08moderate
- SulfasalazineA07EC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01XX11
Tedizolid, as other registers publish it.
- IcelandSivextroMerck Sharp & Dohme B.V.*
- PolandSivextroMerck Sharp & Dohme B.V.
- PolandSivextroMerck Sharp & Dohme B.V.
- FinlandSivextroMerck Sharp & Dohme B.V.
- FinlandSivextroMerck Sharp & Dohme B.V.
- FinlandSivextroMerck Sharp & Dohme B.V.
- DenmarkSivextroMerck Sharp & Dohme B.V.
- IcelandSivextroMerck Sharp & Dohme B.V.*
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df039b4e-2c82-44f9-95fc-ed14a401184c GET /v1/drugs/df039b4e-2c82-44f9-95fc-ed14a401184c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "200 mg",
"auth_role": "MOD",
"dk_drugid": "28105582114",
"substance": "Tedizolidphosphat",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "42086"
}See everything about tedizolid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.